CHAPTER 1. INTRODUCTION
1.1. Market Definition
1.2. Executive Summary
1.3. The Scope of the Study
CHAPTER 2. RESEARCH METHODOLOGY
2.1. Secondary Research
2.2. Primary Research
2.3. Analytic Tools and Model
2.4. Economic Indicator
2.4.1 Base Year, Base Currency, Forecasting Period
2.5. Expert Validation
2.6. Study Timeline
CHAPTER 3. MARKET ANALYSIS
3.1. Industry Value Chain Analysis
3.2. Porter's Five Force Analysis
3.2.1. Bargaining Power of Buyers
3.2.2. Bargaining Power of Suppliers
3.2.3. Threats of Substitutes
3.2.4. Threats of New Entrants
3.2.5. Degree of Competition
3.3. PESTLE Analysis
3.3.1. Political
3.3.2. Economical
3.3.3. Social
3.3.4. Technological
3.3.5. Legal
3.3.6. Environmental
3.4. SWOT Analysis
3.4.1. Strengths
3.4.2. Weakness
3.4.3. Opportunities
3.4.4. Threats
3.5. Y-O-Y Analysis
CHAPTER 4. MARKET DYNAMICS
4.1. Market Drivers
4.1.1. Aggressive marketing by pharma companies
4.1.2. Growing geriatric population
4.1.3. Rising incidence of OAB (Overactive Bladder) diseases
4.1.4. Development of innovative intravesical therapies
4.1.5. Increasing R&D expenditure to develop innovative novel drugs
4.2. Market Restraints & Challenges
4.2.1. Lack of awareness on OAB
4.2.2. Unfavourable side effects of current OAB treatments
4.2.3. Low efficacy of available drugs
4.3. Market Opportunities
4.3.1. Novel treatments, a robust pipeline and the patient cliff of certain drugs
CHAPTER 5. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET – BY
PHARMACOTHERAPY
5.1. Anticholinergics
5.1.1. Solifenacin
5.1.2. Oxybutynin
5.1.3. Fesoterodine
5.1.4. Darifenacin
5.1.5. Tolterodine
5.1.6. Trospium
5.1.7. Others
5.2. Mirabegron
5.2. Botox
5.4. Neurostimulation
5.5. Intravesical Instillation
CHAPTER 6. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET – BY
DISEASE
6.1. Idiopathic OAB
6.2. Neurogenic OAB
6.2.1. OAB in Parkinson’s disease
6.2.2. OAB in Stroke
6.2.3. OAB in Multiple Sclerosis
6.2.4. OAB in Spinal Cord Injury
6.2.5. OAB in Other Disorders
CHAPTER 7. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET - BY
GEOGRAPHY
7.1. Introduction
7.2. North America
7.2.1. U.S.
7.2.2. Canada
7.2.3. Mexico
7.2.4. Costa Rica
7.3. South America
7.3.1. Brazil
7.3.2. Argentina
7.3.3. Chile
7.3.4. Columbia
7.3.5. Others
7.4. Europe
7.4.1. U.K.
7.4.2. Germany
7.4.3. France
7.4.4. Italy
7.4.5. Spain
7.4.6. Russia
7.4.7. Netherlands
7.4.8. Switzerland
7.4.9. Poland
7.4.10. Others
7.5. APAC
7.5.1. China
7.5.2. Japan
7.5.3. India
7.5.4. South Korea
7.5.5. Australia & New Zealand
7.5.6. Malaysia
7.5.7. Singapore
7.5.8. Others
7.6. Middle East & Africa
7.6.1. UAE
7.6.2. Saudi Arabia
7.6.3. Iran
7.6.4. Iraq
7.6.5. Qatar
7.6.6. South Africa
7.6.7. Algeria
7.6.8. Morocco
7.6.9. Nigeria
7.6.10. Egypt
7.6.11. Others
CHAPTER 8. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET -
COMPANY PROFILES
8.1. Allergan PLC
8.2. Astellas Pharma Inc.
8.3. Cogentix Medical Inc.
8.4. Endo International PLC
8.5. Hisamitsu Pharmaceutical Co. Inc.
8.6. Medtronic PLC
8.7. Pfizer Inc.
8.8. Johnson & Johnson
8.9. Sanofi
8.10. Teva Pharmaceutical Industries Ltd.
8.11. Macleods Pharmaceuticals Ltd.
8.12. Mylan N.V.
8.13. Apotex Inc.
8.14. Intas Pharmaceuticals Ltd
8.15. Aurobindo Pharma Ltd
CHAPTER 9. GLOBAL OVERACTIVE BLADDER TREATMENT MARKET -
COMPETITIVE LANDSCAPE
9.1. Market Share Analysis
9.2. Strategies adopted by top companies
9.3. Mergers, Acquisitions, Collaborations & Agreements
CHAPTER 10. MARKET INSIGHTS
10.1. Industry Experts Insights
10.2. Analysts Opinions
10.3. Investment Opportunities
CHAPTER 11. APPENDIX
11.1. List of Tables
11.2. List of Figures
